

Table SI. Inflammatory lesion counts and outcomes of the patients

Patient	M0	20 mg/day				20 mg/every other day		20 mg twice a week		20 mg/week		Follow-up (months)	Relapse
		M1	M2	M3	M4	M5	M6	M7	M8	M9	M10		
1	16	1	0	4	3	0	0	0	0	0	0	7	-
2	2	2	4	0	0	0	2	3	1	5	9	(*)	-
3	16	0	2	2	1	3	2	3	3	1	1	10	-
4	7	0	1	4	1	0	0	0	0	0	1	5	+ (topical)
5	7	2	2	0	1	0	2	0	1	1	-	-	-
6	5	2	1	2	1	0	2	1	1	1	1	2	-
7	20	0	1	0	1	0	0	0	0	0	0	8	-
8	9	3	2	2	0	1	1	0	0	2	2	11	+ (isotretinoin)
9	2	0	0	0	0	0	0	1	0	0	0	5	-
10	8	20	4	6	5	5	8	6	2	2	1	7	+ (isotretinoin)
11	16	4	0	0	0	1	2	0	0	0	1	16	-
12	40	10	5	1	1	0	0	0	1	0	0	17	-
13	7	0	0	0	0	0	0	0	0	1	0	7	+ (topical)
14	6	5	0	0	0	1	4	0	2	9	4	2	+ (isotretinoin)
15	29	6	6	4	3	3	0	0	0	3	3	3	+ (isotretinoin)
16	9	0	1	0	4	5	0	6	2	-	-	-	-
17	42	4	2	1	5	5	4	1	4	3	2	5	-
18	29	10	4	3	5	0	0	1	0	0	0	-	-
19	15	1	0	0	0	2	0	0	0	0	0	3	-
20	10	3	2	3	2	0	0	3	0	5	2	1	+ (cosmetic)
21	11	0	4	2	0	0	0	0	1	0	2	12	-
22	20	0	0	0	0	0	0	0	0	0	0	(*)	-
23	9	4	3	2	1	0	0	0	0	1	0	11	+ (topical)
24	25	7	2	2	0	0	1	0	2	0	0	6	-
25	49	14	3	4	6	2	1	2	2	0	0	9	+ (cosmetic)

*Isotretinoin was not stopped.

Note: Papule and pustule counts were significantly lower [($p=0.000$, power=0.99) and ($p=0.001$, power=0.96) respectively] in the first month of therapy compared with the results of pre-treatment.